

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076

Estimated average burden

hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number)	Previous Names	None	Entity Type
<a href="#">0001541157</a>	Morria Biopharmaceuticals PLC		<input checked="" type="checkbox"/> Corporation <input type="checkbox"/> Limited Partnership <input type="checkbox"/> Limited Liability Company <input type="checkbox"/> General Partnership <input type="checkbox"/> Business Trust <input type="checkbox"/> Other (Specify)
<b>Name of Issuer</b>	Celsus Therapeutics Plc.		
<b>Jurisdiction of Incorporation/Organization</b>	UNITED KINGDOM		
<b>Year of Incorporation/Organization</b>	<input checked="" type="checkbox"/> Over Five Years Ago <input type="checkbox"/> Within Last Five Years (Specify Year) <input type="checkbox"/> Yet to Be Formed		

2. Principal Place of Business and Contact Information

Name of Issuer			
Street Address 1		Street Address 2	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
Celsus Therapeutics Plc.			
53 DAVIES STREET			
LONDON	UNITED KINGDOM	W1K 5JH	+44-207-152-6341

3. Related Persons

Last Name	First Name	Middle Name
Roshwalb	Gur	
Street Address 1	Street Address 2	
c/o Celsus Therapeutics Plc	53 Davies Street	
City	State/Province/Country	ZIP/PostalCode
London	UNITED KINGDOM	W1K 5JH
<b>Relationship:</b> <input checked="" type="checkbox"/> Executive Officer <input type="checkbox"/> Director <input type="checkbox"/> Promoter		

Clarification of Response (if Necessary):

Chief Executive Officer

Last Name	First Name	Middle Name
Elefant	Dov	
Street Address 1	Street Address 2	
c/o Celsus Therapeutics Plc	53 Davies Street	
City	State/Province/Country	ZIP/PostalCode
London	UNITED KINGDOM	W1K 5JH
<b>Relationship:</b> <input checked="" type="checkbox"/> Executive Officer <input type="checkbox"/> Director <input type="checkbox"/> Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Yedgar	Saul	
Street Address 1	Street Address 2	
Department of Biochemistry	Hebrew University-Hadassah Med. School	
City	State/Province/Country	ZIP/PostalCode
Jerusalem	ISRAEL	91120
<b>Relationship:</b> X Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Cohen	Mark	
Street Address 1	Street Address 2	
Pearl Cohen Zedek Latzer, LLP	1500 Broadway, 12th Floor	
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10036
<b>Relationship:</b> Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Lau	Johnson	
Street Address 1	Street Address 2	
701 Ellicott Street		
City	State/Province/Country	ZIP/PostalCode
Buffalo	NEW YORK	14203
<b>Relationship:</b> Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Sidransky	David	
Street Address 1	Street Address 2	
c/o Celsus Therapeutics Plc	53 Davies Street	
City	State/Province/Country	ZIP/PostalCode
London	UNITED KINGDOM	W1K 5JH
<b>Relationship:</b> Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Eiran	Amos	
Street Address 1	Street Address 2	
2 Avner Street		
City	State/Province/Country	ZIP/PostalCode
Herzeliya	ISRAEL	46662
<b>Relationship:</b> Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Harris	Alan	
Street Address 1	Street Address 2	

190 East 72nd Street, Apt. 32C

**City**

**State/Province/Country**

**ZIP/PostalCode**

New York

NEW YORK

10021

**Relationship:**  Executive Officer  Director  Promoter

Clarification of Response (if Necessary):

**Last Name**

**First Name**

**Middle Name**

Doman

Robert

**Street Address 1**

**Street Address 2**

c/o Celsus Therapeutics Plc

53 Davies Street

**City**

**State/Province/Country**

**ZIP/PostalCode**

London

UNITED KINGDOM

W1K 5JH

**Relationship:**  Executive Officer  Director  Promoter

Clarification of Response (if Necessary):

**Last Name**

**First Name**

**Middle Name**

Price

Fredric

**Street Address 1**

**Street Address 2**

c/o Celsus Therapeutics Plc

53 Davies Street

**City**

**State/Province/Country**

**ZIP/PostalCode**

London

UNITED KINGDOM

W1K 5JH

**Relationship:**  Executive Officer  Director  Promoter

Clarification of Response (if Necessary):

#### 4. Industry Group

Agriculture

Health Care

Retailing

Banking & Financial Services

Biotechnology

Restaurants

Commercial Banking

Health Insurance

Technology

Insurance

Hospitals & Physicians

Computers

Investing

Pharmaceuticals

Telecommunications

Investment Banking

Other Health Care

Other Technology

Pooled Investment Fund

Manufacturing

Travel

Is the issuer registered as an investment company under the Investment Company Act of 1940?

Real Estate

Airlines & Airports

Yes

No

Commercial

Lodging & Conventions

Yes

Construction

Tourism & Travel Services

Other Banking & Financial Services

REITS & Finance

Other Travel

Business Services

Residential

Other

Energy

Other Real Estate

Coal Mining

Electric Utilities

Energy Conservation

Environmental Services

Oil & Gas

Other Energy

#### 5. Issuer Size

**Revenue Range**

**OR**

**Aggregate Net Asset Value Range**

<input checked="" type="checkbox"/> No Revenues	No Aggregate Net Asset Value
\$1 - \$1,000,000	\$1 - \$5,000,000
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000
Over \$100,000,000	Over \$100,000,000
Decline to Disclose	Decline to Disclose
Not Applicable	Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)
Rule 505	Section 3(c)(5)	Section 3(c)(13)
Rule 506(b)	Section 3(c)(6)	Section 3(c)(14)
<input checked="" type="checkbox"/> Rule 506(c)	Section 3(c)(7)	
Securities Act Section 4(a)(5)		

7. Type of Filing

New Notice Date of First Sale 2013-09-24 First Sale Yet to Occur  
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes  No

9. Type(s) of Securities Offered (select all that apply)

<input checked="" type="checkbox"/> Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes  No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient	Recipient CRD Number	None
MTS Securities, LLC	104059	
(Associated) Broker or Dealer <input checked="" type="checkbox"/> None	(Associated) Broker or Dealer CRD Number	<input checked="" type="checkbox"/> None
None	None	

**Street Address 1**

623 Fifth Avenue, 14th Floor

**Street Address 2**

City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10022

State(s) of Solicitation (select all that apply)  
Check "All States" or check individual States

All States	Foreign/non-US
------------	----------------

CALIFORNIA
FLORIDA
NEW JERSEY
NEW YORK

Recipient	Recipient CRD Number	None
Oppenheimer & Co. Inc.	249	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None	
None	None	

**Street Address 1**

**Street Address 2**

125 Broad Street, 16th Floor

City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10004

State(s) of Solicitation (select all that apply)  
Check "All States" or check individual States

All States	Foreign/non-US
------------	----------------

CALIFORNIA
FLORIDA
NEW JERSEY
NEW YORK

13. Offering and Sales Amounts

Total Offering Amount	\$12,516,232 USD	or	Indefinite
Total Amount Sold	\$12,516,232 USD		
Total Remaining to be Sold	\$0 USD	or	Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

18

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$876,136 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

MTS Securities, LLC served as lead placement agent and Oppenheimer & Co. acted as co-placement agent for the Issuer.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$180,000 USD

## Clarification of Response (if Necessary):

For back pay and reimbursement of expenses for officers.

## Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

## Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Celsus Therapeutics Plc.	/s/ Dov Elefant	Dov Elefant	Chief Financial Officer	2013-09-30

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.